SAN

96.15

-3.49%↓

EI

244.1

-1.89%↓

SHL.DE

44.49

-4.08%↓

ARGX

520.2

-2.91%↓

FRE

38.02

-4.35%↓

SAN

96.15

-3.49%↓

EI

244.1

-1.89%↓

SHL.DE

44.49

-4.08%↓

ARGX

520.2

-2.91%↓

FRE

38.02

-4.35%↓

SAN

96.15

-3.49%↓

EI

244.1

-1.89%↓

SHL.DE

44.49

-4.08%↓

ARGX

520.2

-2.91%↓

FRE

38.02

-4.35%↓

SAN

96.15

-3.49%↓

EI

244.1

-1.89%↓

SHL.DE

44.49

-4.08%↓

ARGX

520.2

-2.91%↓

FRE

38.02

-4.35%↓

SAN

96.15

-3.49%↓

EI

244.1

-1.89%↓

SHL.DE

44.49

-4.08%↓

ARGX

520.2

-2.91%↓

FRE

38.02

-4.35%↓

Search

Pharma Mar SA

Closed

75.5 -3.08

Overview

Share price change

24h

Current

Min

72.8

Max

78

Key metrics

By Trading Economics

Income

5.7M

9.5M

Sales

2.7M

48M

P/E

Sector Avg

1,996.25

63.778

EPS

1.063

Dividend yield

0.81

Profit margin

19.737

Employees

500

EBITDA

8.2M

15M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+38.73% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.81%

2.39%

Next Earnings

22 kwi 2025

Market Stats

By TradingEconomics

Market Cap

1.4B

Previous open

78.58

Previous close

75.5

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

Pharma Mar SA Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

4 kwi 2025, 22:38 UTC

Hot Stocks

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

4 kwi 2025, 21:53 UTC

Market Talk

Maxeon's Supply Chain Move at Critical Time for Solar Panel Cos -- Market Talk

4 kwi 2025, 21:44 UTC

Top News
Acquisitions, Mergers, Takeovers

Trump Grants 75-Day Extension to Reach TikTok Deal -- 3rd Update

4 kwi 2025, 21:00 UTC

Top News

Americans Were Souring on Trump's Economic Plans Even Before Tariff Bloodbath -- WSJ

4 kwi 2025, 20:52 UTC

Market Talk

Peloton Likely to Escape Tariffs Unscathed -- Market Talk

4 kwi 2025, 20:52 UTC

Top News

Trump Can Cut Teacher-Training Programs For Now, Supreme Court Says -- WSJ

4 kwi 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 kwi 2025, 20:48 UTC

Top News

The Score: Nike, Apple, Stellantis and More Stocks That Defined the Week -- WSJ

4 kwi 2025, 20:45 UTC

Top News

Hiring Defied Expectations in March, With 228,000 New Jobs -- 6th Update

4 kwi 2025, 20:32 UTC

Top News

Dow Tumbles 2,000 Points, Bonds Rally After China Retaliates Against Trump Tariffs -- WSJ

4 kwi 2025, 20:21 UTC

Top News

China Hits Back at Trump With Sweeping Tariffs on All U.S. Goods -- Update

4 kwi 2025, 20:00 UTC

Top News

Republicans March Ahead on Trump's Tax Cuts as Tariffs Kick In -- WSJ

4 kwi 2025, 19:51 UTC

Market Talk

Dollar Recovers While Recession Fears Grip Wall Street -- Market Talk

4 kwi 2025, 19:37 UTC

Top News

Trump's Team is Getting the Bond Rally It Wanted. But for the Wrong Reasons. -- WSJ

4 kwi 2025, 19:32 UTC

Market Talk

Oil Selloff Continues as China Responds to U.S. Tariffs -- Market Talk

4 kwi 2025, 19:28 UTC

Top News

U.S. Stocks Fall Further After China Retaliates Against Trump Tariffs -- Update

4 kwi 2025, 19:15 UTC

Market Talk

Costco Gold, Membership Fees Could Help Cushion from Tariff Costs -- Market Talk

4 kwi 2025, 19:12 UTC

Top News

Powell Warns of Higher Prices, Weaker Growth After Tariff Plan -- 3rd Update

4 kwi 2025, 19:11 UTC

Market Talk

U.S. Natural Gas Falls as Global Selloff Continues -- Market Talk

4 kwi 2025, 19:09 UTC

Market Talk

Mexican Stocks, Peso Tumble as Global Rout Continues -- Market Talk

4 kwi 2025, 19:09 UTC

Top News

Trump Grants 75-Day Extension to Reach TikTok Deal -- Second Update

4 kwi 2025, 19:00 UTC

Market Talk

Fed Has Limited Options to Counter Tariffs -- Market Talk

4 kwi 2025, 18:53 UTC

Market Talk

Brace for Trump's Tariff Order to Remain in Place for Extended Period -- Market Talk

4 kwi 2025, 18:51 UTC

Market Talk

Morgan Stanley Analysts Outline Paths to Recession -- Market Talk

4 kwi 2025, 18:44 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

4 kwi 2025, 18:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 kwi 2025, 18:44 UTC

Market Talk

Tariffs Won't Achieve What Trump Wants, Morgan Stanley Says -- Market Talk

4 kwi 2025, 18:43 UTC

Acquisitions, Mergers, Takeovers

Trump Extends Deadline for TikTok Ban Another 75 Days. ByteDance Says 'An Agreement Has Not Been Executed.' -- Barrons.com

4 kwi 2025, 18:43 UTC

Acquisitions, Mergers, Takeovers

Trump Extends TikTok Ban Deadline A Second Time As Deal Chatter Swirls -- IBD

4 kwi 2025, 18:39 UTC

Market Talk

Protectionism is Back, And Recession Could Follow, Morgan Stanley Says -- Market Talk

Peer Comparison

Price change

Pharma Mar SA Forecast

Price Target

By TipRanks

38.73% upside

12 Months Forecast

Average 108.002 EUR  38.73%

High 108 EUR

Low 108 EUR

Based on 1 Wall Street analysts offering 12 month price targets forPharma Mar SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

76.8 / 80.7Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Very Strong Bearish Evidence

Long Term

Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Pharma Mar SA

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.